Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Subcontract opportunity from Department Of Veterans Affairs was posted on August 28, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Droxidopa Capsule Manufacturing

Closed
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412
New
Federal
6505--Request for Information (RFI) - Specialty – PPV 2028 Amendment 0002 to Extend Response Date from Nov. 16, 2026 to Nov. 30, 2026 at 11AM CT
Solicitation # 36E79727Q0001
The Department of Veterans Affairs, through the OALC Enterprise Procurement Office, has issued a Request for Information regarding the Pharmaceutical Prime Vendor (PPV) 2028 program. The agency is seeking market research to determine the feasibility of integrating Limited Distribution and Closed Distribution Products (CDP) into the PPV scope. These specialty medications are typically high-cost, low-volume items with restricted distribution channels that often require specific clinical justifications, manufacturer-mandated registrations, and specialized safety monitoring. The primary objective is to establish a seamless ordering platform where all Federal Supply Schedule (FSS) items, including those that bypass the physical possession of the prime vendor, are visible and orderable with accurate invoicing and delivery tracking for VA medical centers nationwide. The government is soliciting detailed feedback from industry partners on their ability to coordinate fulfillment with manufacturer-designated specialty distributors and their capacity to provide consistent reporting and reconciliation for these transactions. Potential respondents must provide their company name, point of contact information, UEI, CAGE code, and any applicable socioeconomic designations. Submissions are due by 11 AM Central on November 16, 2026, via email to Karen Ade. This notice is strictly for market research purposes and does not constitute a formal solicitation or a commitment by the government to award a contract.
Nac Prime Vendor (36W797)

POSTED

1 day ago

DEADLINE

in 20 days

AI Contract Overview

Show more

This subcontract involves the manufacturing of Droxidopa oral capsules in 100MG and 200MG dosages for prime contractors supporting Department of Veterans Affairs pharmaceutical procurement projects. The scope of work includes the measuring, weighing, mixing, and compounding of pharmaceutical-grade capsules within FDA-compliant facilities to ensure all government specifications are met. Key requirements for the provider include maintaining TAA compliance and assigning a unique eleven-digit National Drug Code to the products. The resulting bulk pharmaceutical capsules will be delivered to support VA operations, with performance centered in Hines, Illinois.

General Info

Manufacturing FDA-compliant Droxidopa capsules for VA projects, ensuring TAA and NDC compliance.

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

Hines, IL, 60141

Set-Aside

NONE

Documents

This scope was carved out of 36E79726Q0004.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

6505--Droxidopa Capsules (VA-27-00007975)

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

subcontract

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → Nac Pharmaceuticals (36E797)
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Manufactures Droxidopa 100MG and 200MG oral capsules for prime contractors on Department of Veterans Affairs (VA) pharmaceutical procurement projects. Measures, weighs, mixes, and compounds pharmaceutical-grade capsules in FDA-compliant facilities. Requires provision of a unique eleven-digit National Drug Code (NDC) and TAA compliance. Delivers bulk pharmaceutical capsules meeting government specifications.

More opportunities from Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)

Same awarding agency

NAICS: 325412
Federal
6505--Latanoprost Ophthalmic Solution (VA-27-00006027)
Solicitation # 36E79727R0039
The Department of Veterans Affairs is soliciting proposals for the procurement of Latanoprost 0.005% Ophthalmic Solution to ensure an uninterrupted supply for the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted commercial item procurement is structured into two groups, with one award made in the aggregate for either Group I (single bottles) or Group II (single and bulk cartons). The resulting contract will consist of a one-year base period followed by four pre-priced one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs, requiring the contractor to deliver supplies to designated distribution centers based on business-to-business agreements. Award will be granted based on the lowest evaluated price among proposals that meet all non-cost acceptability standards. Offerors must provide a unique 11-digit NDC number and adhere to the American Academy of Ophthalmology’s uniform color-coding system for caps and labels. Strict compliance with FDA current Good Manufacturing Practice standards is required, and offerors must certify they possess the necessary NDA, ANDA, or BLA approvals. Additionally, products must meet rigorous barcoding and serialization requirements under the Drug Supply Chain Security Act, including the use of GS-1 data matrix codes. Proposals must be submitted by November 17, 2026, and must include a 0.5% cost recovery fee embedded in the pricing.
Pharmaceutical Preparation Manufacturing

POSTED

11 days ago

DEADLINE

in 7 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS